Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Intensive Care Medicine|May 18, 2001
Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemiaM Theisen, K Träger, I Tugtekin, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 11, 2011
Absence of indigenous specific West Nile virus antibodies in Tyrolean blood donorsS T Sonnleitner, J Simeoni, E Schmutzhard, et al.
Oncology|November 27, 1999
Combined treatment of metastatic osteosarcoma of the spineT Bauernhofer, H Stöger, A K Kasparek, et al.
Intensive Care Medicine|May 10, 2003
Effect of combining nicotinamide as a PARS-inhibitor with selective iNOS blockade during porcine endotoxemiaA Stehr, F Ploner, I Tugtekin, et al.
Shock (Augusta, Ga.)|September 4, 2001
Effects of selective iNOS inhibition on gut and liver O2-exchange and energy metabolism during hyperdynamic porcine endotoxemiaM Matejovic, P Radermacher, I Tugtekin, et al.
Intensive Care Medicine|June 12, 2001
Increased ileal-mucosal-arterial PCO2 gap is associated with impaired villus microcirculation in endotoxic pigsI F Tugtekin, P Radermacher, M Theisen, et al.
Wiener Klinische Wochenschrift|January 1, 1994
[Breast cancer in the man: a report of 30 patients]H Stöger, T Bauernhofer, R Moser, et al.
Journal of Cancer Research and Clinical Oncology|May 14, 2013
The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS)F Ploner, W Lamm, S Schur, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patientsH Stöger, T Bauernhofer, M Schmid, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II studyH Stöger, T Bauernhofer, A K Kasparek, et al.
Pageof 3